机构:[1]Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.华中科技大学同济医学院附属同济医院[2]Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.[3]Beijing Tongren Eye Center, Beijing Tongren Hospital, Capital Medical University, Beijing Ophthalmology & Visual Science Key Lab, Beijing, China.首都医科大学附属北京同仁医院首都医科大学附属同仁医院[4]Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China华中科技大学同济医学院附属同济医院[5]Nanjing IASO Biotechnology Co. Ltd., Nanjing, China.[6]Department of Pathogen Biology, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.[7]Department of Neurology with Institute of Translational Neurology, University Hospital Münster, Münster, Germany.[8]Department of Neurology, Mayo Clinic, Rochester, MN 55905, USA.[9]Shanghai Immune Therapy Institute, Shanghai Jiaotong University School of Medicine–affiliated Renji Hospital, Shanghai, China.
Chimeric antigen receptor (CAR) T cell immunotherapy for the treatment of neurological autoimmune diseases is promising, but CAR T cell kinetics and immune alterations after treatment are poorly understood. Here, we performed single-cell multi-omics sequencing of paired cerebrospinal fluid (CSF) and blood samples from patients with neuromyelitis optica spectrum disorder (NMOSD) treated with anti-B cell maturation antigen (BCMA) CAR T cells. Proliferating cytotoxic-like CD8+ CAR T cell clones were identified as the main effectors in autoimmunity. Anti-BCMA CAR T cells with enhanced features of chemotaxis efficiently crossed the blood-CSF barrier, eliminated plasmablasts and plasma cells in the CSF, and suppressed neuroinflammation. The CD44-expressing early memory phenotype in infusion products was potentially associated with CAR T cell persistence in autoimmunity. Moreover, CAR T cells from patients with NMOSD displayed distinctive features of suppressed cytotoxicity compared with those from hematological malignancies. Thus, we provide mechanistic insights into CAR T cell function in patients with neurological autoimmune disease.
基金:
STI2030-Major Projects 2022ZD0204700 (Wei Wang), National Natural Science Foundation of China (grants 82371404 and 82071380 to D.-S.T. and 82271341 to C.Q.), Hubei Province Key Research and Development Program Project
(2023BCB148 to D.-S.T.), Basic Research Support Program of Huazhong University of Science and Technology (to C.Q.), and Knowledge Innovation Program of Wuhan Shuguang Project (2022020801020454 to C.Q.).
第一作者机构:[1]Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.[2]Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.
共同第一作者:
通讯作者:
通讯机构:[1]Department of Neurology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China.[2]Hubei Key Laboratory of Neural Injury and Functional Reconstruction, Huazhong University of Science and Technology, Wuhan 430030, China.
推荐引用方式(GB/T 7714):
Qin Chuan,Zhang Min,Mou Da-Peng,et al.Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity[J].SCIENCE IMMUNOLOGY.2024,9(95):eadj9730.doi:10.1126/sciimmunol.adj9730.
APA:
Qin Chuan,Zhang Min,Mou Da-Peng,Zhou Luo-Qi,Dong Ming-Hao...&Wang Wei.(2024).Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity.SCIENCE IMMUNOLOGY,9,(95)
MLA:
Qin Chuan,et al."Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity".SCIENCE IMMUNOLOGY 9..95(2024):eadj9730